MedPath

Effect of rTMS in Combination With a Low-carbohydrate Diet in Patients With Obesity

Not Applicable
Completed
Conditions
Obesity
Anxiety
Registration Number
NCT03345368
Lead Sponsor
Hospital General Ajusco Medio
Brief Summary

In the present study the investigators want to evaluate if the application of rTMS can reduce the anxiety and craving in patients with obesity helping them to follow a low carb-diet, as well as, to assess the changes in weight, body mass index and quality of life before and after rTMS or sham rTMS.

Detailed Description

Participants completed a written, informed consent and rTMS adult safety questionnaire. The inclusion criteria are:

individuals between 25 and 60 years of age with obesity in stage 1, 2 or 3. The exclusion criteria were: subjects with metabolic disorders, neurological condition, epilepsy, or pregnancy. The study conformed to the Declaration of Helsinki and was approved by the Institutional Medical Research Ethics Committee (Hospital Ajusco Medio, Mexico DF). The protocol will be applied as follows: 10 rTMS or sham sessions during two weeks. Following these two week, patients will receive 8 more sessions on weeks 4, 6, 8, 10, 12, 16, 20 and 24. Diet will be indicated during all the protocol. The sham group will receive sham rTMS sessions for two weeks, the additional sessions will be performed in the same manner thar in rTMS group.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
49
Inclusion Criteria
  • BMI > 30
Exclusion Criteria
  • Thyroid problems, anorexia, bulimia, epilepsy, schizophrenia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Obesity, changes in the body mass index7 days

Obesity is a body mass index greater than or equal to 30.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hospital General Ajusco Medio

🇲🇽

Mexico, Tlalpan, Mexico

Hospital General Ajusco Medio
🇲🇽Mexico, Tlalpan, Mexico

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.